# Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

> **NCT02154776** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** LEE011
- **DRUG:** Buparlisib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02154776
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-27
- **Primary completion:** 2016-10-26
- **Final completion:** 2016-10-26
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02154776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02154776, "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02154776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*